Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...
Hosted on MSN11h
Eli Lilly: 4 Reasons Investors Shouldn't Miss This OpportunityEli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
Hosted on MSN22h
Pharma Market Forecast: Top Trends for Pharma in 2025The pharmaceutical industry is poised for a dynamic year in 2025. A confluence of positive trends suggests a brighter outlook ...
Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...
Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
Kroger settles an opioid lawsuit in Kentucky for $110 million. The U.S. builds a bird flu vaccine stockpile. Shanghai permits ...
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...
The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback